FGFR2 and adenomyosis: The mutation frequencies per subject, regardless of sampling depths, were as follows: in adenomyosis, KRAS: 33.3%, PIK3CA: 14.3%, and ARID1A: 14.3%, and in uterine endometrium, KRAS: 66.7%, PIK3CA: 57.1%, ARHGAP35: 52.4%, PPP2R1A: 33.3%, PIK3R1: 28.6%, and FGFR2: 19.0% (Fig. 2).